Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Refractory anemia with ring sideroblasts and marked thrombocytosis cases harbor mutations in SF3B1 or other spliceosome genes accompanied by JAK2V617F and ASXL1 mutations.
Jeromin S, Haferlach T, Weissmann S, Meggendorfer M, Eder C, Nadarajah N, Alpermann T, Kohlmann A, Kern W, Haferlach C, Schnittger S. Jeromin S, et al. Among authors: alpermann t. Haematologica. 2015 Apr;100(4):e125-7. doi: 10.3324/haematol.2014.119032. Epub 2014 Dec 19. Haematologica. 2015. PMID: 25527566 Free PMC article. No abstract available.
Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow.
Schnittger S, Bacher U, Eder C, Dicker F, Alpermann T, Grossmann V, Kohlmann A, Kern W, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: alpermann t. Haematologica. 2012 Oct;97(10):1582-5. doi: 10.3324/haematol.2012.064683. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511494 Free PMC article.
Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases.
Schnittger S, Bacher U, Alpermann T, Reiter A, Ulke M, Dicker F, Eder C, Kohlmann A, Grossmann V, Kowarsch A, Kern W, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: alpermann t. Haematologica. 2012 Dec;97(12):1890-4. doi: 10.3324/haematol.2012.065375. Epub 2012 Jun 24. Haematologica. 2012. PMID: 22733026 Free PMC article.
High frequencies of SF3B1 and JAK2 mutations in refractory anemia with ring sideroblasts associated with marked thrombocytosis strengthen the assignment to the category of myelodysplastic/myeloproliferative neoplasms.
Jeromin S, Haferlach T, Grossmann V, Alpermann T, Kowarsch A, Haferlach C, Kern W, Schnittger S. Jeromin S, et al. Among authors: alpermann t. Haematologica. 2013 Feb;98(2):e15-7. doi: 10.3324/haematol.2012.072538. Epub 2012 Aug 28. Haematologica. 2013. PMID: 22929973 Free PMC article. No abstract available.
Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S, Alpermann T, Grossmann V, Kowarsch A, Nadarajah N, Eder C, Dicker F, Fasan A, Haferlach C, Haferlach T, Kern W, Schnittger S, Kohlmann A. Weissmann S, et al. Among authors: alpermann t. Leukemia. 2012 May;26(5):934-42. doi: 10.1038/leu.2011.326. Epub 2011 Nov 25. Leukemia. 2012. PMID: 22116554
ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome.
Schnittger S, Eder C, Jeromin S, Alpermann T, Fasan A, Grossmann V, Kohlmann A, Illig T, Klopp N, Wichmann HE, Kreuzer KA, Schmid C, Staib P, Peceny R, Schmitz N, Kern W, Haferlach C, Haferlach T. Schnittger S, et al. Among authors: alpermann t. Leukemia. 2013 Jan;27(1):82-91. doi: 10.1038/leu.2012.262. Epub 2012 Sep 11. Leukemia. 2013. PMID: 23018865
The role of different genetic subtypes of CEBPA mutated AML.
Fasan A, Haferlach C, Alpermann T, Jeromin S, Grossmann V, Eder C, Weissmann S, Dicker F, Kohlmann A, Schindela S, Kern W, Haferlach T, Schnittger S. Fasan A, et al. Among authors: alpermann t. Leukemia. 2014 Apr;28(4):794-803. doi: 10.1038/leu.2013.273. Epub 2013 Sep 23. Leukemia. 2014. PMID: 24056881
106 results